Cloud-Computing: eHealth aus der Wolke

2018 ◽  
Vol 23 (11) ◽  
pp. 38-41
Author(s):  
Sebastian Krolop ◽  
Florian Benthin ◽  
Constanze Knahl

Cloud-Computing gewinnt auch in Kliniken zunehmend an Bedeutung. Über das Internet bereitgestellte Lösungen verändern nicht nur Verwaltung und Logistik – im klinischen Bereich geht es zum Beispiel um die Nutzung elektronischer Patientenakten am Point-of-Care.

2019 ◽  
Author(s):  
Md Kamrul Hasan ◽  
Md Hasanul Aziz ◽  
Md Ishrak Islam Zarif ◽  
Mahmudul Hasan ◽  
M. M. A. Hashem ◽  
...  

BACKGROUND In the USA, 5.6% of the population is anemic; 1.5% has moderate-severe anemia. Globally, 1.62 billion people are affected by Hb diseases. Clinical assessment of hemoglobin levels, using the cyan-methemoglobin method is reliable, but the process is not portable, results are not immediately available, and this test is unaffordable, and cost-ineffective for most patients in low- and middle-income countries who might benefit. When medical facilities and financial resources are available, frequent repeated testing is less than convenient under this method. In the presence of serious illness, with demands for repeated testing, the delays in obtaining results and the associated blood loss are particular drawbacks of this testing method. In these multiple circumstances, the potential advantages of a non-invasive, point-of-care (POC) method for hemoglobin measurement are clear. There are currently commercial non-invasive POC tools available for non-invasive Hb measurements. Most of these tools have one or more of the following limitations:1) challenging data collection methods; 2) complex data analysis and feature extraction processes; 3) affordability and portability; and 4) lack of user-friendliness and costly external modules. OBJECTIVE Investigate several hemoglobin measurement techniques based on smartphone devices, which have encountered significant challenges in theoretical foundation, data collection methods and sensors, data-signal analysis processes, and machine-learning algorithms. Our objective is to We identify these issue, define specific recommendations for practical solution development, and offer a conceptual framework for a noninvasive hemoglobin level estimation system using different types of smartphones and cloud computing paradigm. METHODS Growing interest and potential low cost of non-invasive hemoglobin measurement solutions has encouraged their development for low-resource settings, where the use of smartphones has increased rapidly. In such settings, the smartphone offers the possibility of an affordable, portable, and reliable point-of-care tool with leveraging its camera capacity, computing power, and lighting sources. However, several hemoglobin measurement techniques based on smartphone devices have encountered significant challenges in theoretical foundation, data collection methods and sensors, data-signal analysis processes, and machine-learning algorithms. We address these issues to define specific recommendations for practical solution development. Finally, we offer a conceptual framework for a noninvasive hemoglobin level estimation system using different types of smartphones and cloud computing paradigm. RESULTS Based on the foregoing review and other considerations, we suggested methods for body site selection for signal acquisition, response or signal, signal processing, theoretical foundations, feature generation, and machine learning algorithm selection. We also propose a conceptual framework for a noninvasive hemoglobin level estimation system using different types of smartphones and cloud computing paradigm. CONCLUSIONS As a growing widely available computing platform, the smartphone offers an alternative, non-invasive point-of-care tool to traditional measurements of blood hemoglobin. We recommend fingertip as a data collection site due to easy access, use of three different NIR lighting sources, specific signal processing techniques and feature selection methods, and region of interest selection methods, for the optimal development of an accurate hemoglobin prediction model. We point out the theoretical foundation, which can be applied for the identification of several blood constituent levels non-invasively. We suggest a conceptual framework for a non-invasive Hb level estimation system using different types of smartphones and a cloud computing paradigm. Investigators need to consider the following issues before developing such a Smartphone-based POC tool: (1) Cost of the smartphone, the external device, reagents if needed, and training, internet, and cloud implementation. (2) Patient’s other physiological features. (3) Allowing the user to do multiple checks and be challenged with a minimal cognitive load. (4) Including the user’s location, sex, and age in the stored record. (5) Keeping the external device as optional so that a user can run a diagnostic without the device. (6) Creating an external device that is cost-effective, easily attachable, properly fit with the finger, and user-friendly.


VASA ◽  
2011 ◽  
Vol 40 (6) ◽  
pp. 429-438 ◽  
Author(s):  
Berent ◽  
Sinzinger

Based upon various platelet function tests and the fact that patients experience vascular events despite taking acetylsalicylic acid (ASA or aspirin), it has been suggested that patients may become resistant to the action of this pharmacological compound. However, the term “aspirin resistance” was created almost two decades ago but is still not defined. Platelet function tests are not standardized, providing conflicting information and cut-off values are arbitrarily set. Intertest comparison reveals low agreement. Even point of care tests have been introduced before appropriate validation. Inflammation may activate platelets, co-medication(s) may interfere significantly with aspirin action on platelets. Platelet function and Cox-inhibition are only some of the effects of aspirin on haemostatic regulation. One single test is not reliable to identify an altered response. Therefore, it may be more appropriate to speak about “treatment failure” to aspirin therapy than using the term “aspirin resistance”. There is no evidence based justification from either the laboratory or the clinical point of view for platelet function testing in patients taking aspirin as well as from an economic standpoint. Until evidence based data from controlled studies will be available the term “aspirin resistance” should not be further used. A more robust monitoring of factors resulting in cardiovascular events such as inflammation is recommended.


2003 ◽  
Vol 23 (04) ◽  
pp. 181-185 ◽  
Author(s):  
H. Patscheke
Keyword(s):  

ZusammenfassungUnabhängig von ihrem Wirkungsmechanismus greifen Antikoagulanzien stets unmittelbar in die Bildung und Wirkung von Thrombin und damit die Endstrecke der Gerinnung ein. Von den Aggregationshemmern hemmen nur die GPIIb/IIIa-Antagonisten die gemeinsame Endstrecke der Plättchenaggregation, indem sie die Bildung von Fibrinogen/von-Willebrand-Faktor-vermittelten Plättchen-Plättchen-Brücken hemmen.Azetylsalizylsäure (ASS), NSARs, Clopidogrel oder Ticlopidin begrenzen die Plättchenaktivierung dagegen, indem sie die Bildung bzw. Wirkung der sekundären Plättchenagonisten Thromboxan A2 bzw. ADP ausschalten, aber z. B. die durch Thrombin direkt induzierbare Plättchenaggregation nicht. Deshalb rufen ASS, Clopidogrel oder Ticlopidin allein kein wesentliches Blutungsrisiko hevor, wenn nicht weitere, die Hämostase beeinträchtigende Faktoren (z.B. ausgeprägte Thrombozytopenie, Antikoagulation) vorliegen. Deshalb entfällt für diese Hemmstoffe auch die Notwendigkeit der Therapiekontrolle. Beim therapeutischen Einsatz von ASS als Aggregationshemmer ist vielmehr die Dosierung darauf abzustellen, eine vollständige Blockade (mind. 90%) der Thromboxanbiosynthese in den Plättchen zu erreichen, um überhaupt einen therapeutischen bzw. prophylaktischen Effekt zu erzielen.Von den GPIIb/IIIa-Antagonisten sind nur die parenteral eingesetzten (Abciximab, Eptifibatid, Tirofiban) zugelassen. Orale GPIIb/IIIa-Antagonisten zeigten bisher in klinischen Studien ein erhöhtes Blutungsrisiko bei nicht ausreichendem therapeutischen Nutzen. Die meisten GPIIb/IIIa-Antagonisten verursachen eine leichte Thrombozytopenie, als deren Auslöser die Inhibitor-Rezeptor-Wechselwirkung bzw. immunologische Mechanismen diskutiert werden. Für das spezifische Monitoring dieser potenten Aggregationshemmer ist ein »Point-of-Care«-Testsystem verfügbar. Für die Einschätzung des Blutungsrisikos müssen jedoch stets alle, die Hämostase beeinflussende Faktoren berücksichtigt werden. Das gilt insbesondere, wenn neben GPIIb/IIIa-Antagonisten Heparin u.a. Wirkstoffe eingesetzt werden.


2017 ◽  
Vol 04 (05) ◽  
pp. 22-22
Keyword(s):  

ZusammenfassungDurch die Etablierung „exzellent ausgebildeter Pflegeperson am point of care“ verbessert sich die Versorgung nachweislich. Die Fachgesellschaft fordert daher pro Fachstation eine Pflegeperson mit mindestens Bachelorabschluss.


Sign in / Sign up

Export Citation Format

Share Document